Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112915802 | 11291580 | 2 | F | 2015 | 20160719 | 20150722 | 20160727 | EXP | US-ASTRAZENECA-2015SE69980 | ASTRAZENECA | 74.00 | YR | F | Y | 69.40000 | KG | 20160727 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112915802 | 11291580 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 250 MCG / 1.2 ML; 1.2 ML EVERY 12 HOURS | U | U | 21773 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||
| 112915802 | 11291580 | 2 | C | WOMANS MULTIVITAMIN FOR 50+ | 2 | DAILY | 0 | ||||||||||||
| 112915802 | 11291580 | 3 | C | CARVIDILOL | 2 | 3.125 MG EVERY 12 HOURS | 0 | ||||||||||||
| 112915802 | 11291580 | 4 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 81 | MG | QD | ||||||||
| 112915802 | 11291580 | 5 | C | PLAVIX | CLOPIDOGREL BISULFATE | 1 | Oral | 0 | 75 | MG | QD | ||||||||
| 112915802 | 11291580 | 6 | C | IRON | IRON | 1 | Oral | 65 MG EVERY 6 HOURS | 0 | ||||||||||
| 112915802 | 11291580 | 7 | C | VITAMIN E | .ALPHA.-TOCOPHEROL | 1 | Oral | 0 | 400 | MG | QD | ||||||||
| 112915802 | 11291580 | 8 | C | ENALOPRIL | 2 | Oral | 0 | 10 | MG | QD | |||||||||
| 112915802 | 11291580 | 9 | C | ATORVASTATIN | ATORVASTATIN | 1 | Oral | DAILY | 0 | ||||||||||
| 112915802 | 11291580 | 10 | C | QUININE SULFATE. | QUININE SULFATE | 1 | Oral | 2 UNK AT NIGHT | 0 | ||||||||||
| 112915802 | 11291580 | 11 | C | VITAMIN D3 | CHOLECALCIFEROL | 1 | Oral | 0 | 500 | MG | QD | ||||||||
| 112915802 | 11291580 | 12 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 0 | 12 | IU | QD | ||||||||
| 112915802 | 11291580 | 13 | C | TRENTAL | PENTOXIFYLLINE | 1 | Oral | 430 MG EVERY 6 HOURS | 0 | ||||||||||
| 112915802 | 11291580 | 14 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 112915802 | 11291580 | 15 | C | NORCO | ACETAMINOPHENHYDROCODONE BITARTRATE | 1 | Oral | 1 UNK DAILY | 0 | ||||||||||
| 112915802 | 11291580 | 16 | C | DIAZEPAM. | DIAZEPAM | 1 | 5 MGEVERY 12 HOURS | 0 | |||||||||||
| 112915802 | 11291580 | 17 | C | AUGMENTIN | AMOXICILLINCLAVULANATE POTASSIUM | 1 | Oral | 850 MG, TWICE A DAY | 0 | ||||||||||
| 112915802 | 11291580 | 18 | C | ROCEPHIN | CEFTRIAXONE SODIUM | 1 | Intravenous (not otherwise specified) | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112915802 | 11291580 | 1 | Diabetes mellitus |
| 112915802 | 11291580 | 2 | Therapy cessation |
| 112915802 | 11291580 | 3 | Blood pressure abnormal |
| 112915802 | 11291580 | 4 | Anticoagulant therapy |
| 112915802 | 11291580 | 5 | Anticoagulant therapy |
| 112915802 | 11291580 | 6 | Iron deficiency |
| 112915802 | 11291580 | 7 | Therapy cessation |
| 112915802 | 11291580 | 8 | Blood pressure abnormal |
| 112915802 | 11291580 | 9 | Blood cholesterol abnormal |
| 112915802 | 11291580 | 10 | Muscle spasms |
| 112915802 | 11291580 | 11 | Therapy cessation |
| 112915802 | 11291580 | 12 | Diabetes mellitus |
| 112915802 | 11291580 | 13 | Muscle spasms |
| 112915802 | 11291580 | 14 | Blood pressure abnormal |
| 112915802 | 11291580 | 15 | Pain |
| 112915802 | 11291580 | 16 | Anxiety |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112915802 | 11291580 | HO |
| 112915802 | 11291580 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112915802 | 11291580 | Drug dose omission | |
| 112915802 | 11291580 | Peripheral artery occlusion | |
| 112915802 | 11291580 | Skin discolouration | |
| 112915802 | 11291580 | Urinary tract infection | |
| 112915802 | 11291580 | Weight decreased | |
| 112915802 | 11291580 | Wound |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 112915802 | 11291580 | 1 | 2006 | 0 | ||
| 112915802 | 11291580 | 3 | 2010 | 0 | ||
| 112915802 | 11291580 | 4 | 2010 | 0 | ||
| 112915802 | 11291580 | 5 | 2010 | 0 | ||
| 112915802 | 11291580 | 6 | 2013 | 0 | ||
| 112915802 | 11291580 | 9 | 2013 | 0 | ||
| 112915802 | 11291580 | 10 | 2006 | 0 | ||
| 112915802 | 11291580 | 11 | 2013 | 0 | ||
| 112915802 | 11291580 | 12 | 2005 | 0 | ||
| 112915802 | 11291580 | 13 | 2013 | 0 | ||
| 112915802 | 11291580 | 14 | 201503 | 0 | ||
| 112915802 | 11291580 | 16 | 2010 | 0 | ||
| 112915802 | 11291580 | 17 | 20160616 | 0 | ||
| 112915802 | 11291580 | 18 | 20160719 | 0 |